The global market for neutropenia treatment is projected to experience a notable growth, climbing up from an evaluation of US$ 16.2 Billion in 2024 to an expected level of US$ 25.9 Billion by 2034. This discernable upward trend is largely propelled by the rising incidence of cancer cases across the globe. Cancer patients, particularly those…